Innova Therapeutics

SC - Mt. PleasantBiotechnology1 H-1B visas (FY2023)

Focus: Innova Therapeutics is a publicly-traded biotech founded in 2020 headquartered in Mt. Pleasant, SC, with a diverse portfolio spanning oncology monoclonal antibodies, talc-based products, radiopharmaceuticals, and early-stage biotech devices. The company operates across multiple therapeutic modalities with limited disclosed scale metrics.

Oncology

Profile data last refreshed 13h ago · AI intelligence enriched 2w ago

Funding Stage

PUBLIC

Open Jobs

About Innova Therapeutics

AI assessmentNot Hiring

No open roles listed right now. Follow Innova Therapeutics to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

2/9 — Limited

Company HealthSolid

Pipeline

Early-stage

21 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Key Products

TALC

Not specified

LOE Approaching

Foundational talc product approaching loss of exclusivity; revenue cliff likely imminent.

Help build intelligence for Innova Therapeutics

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Watch Out For

Zero currently open job requisitions signals minimal near-term hiring and potential organizational constraints or restructuring phase.
Heavy portfolio concentration in Phase 1 bioavailability studies ('healthy subjects' testing) and early-stage devices suggests limited clinical validation and uncertain go-to-market viability.
Two products approaching loss of exclusivity (TALC, SCLEROSOL) without clear late-stage oncology pipeline depth creates patent cliff risk despite core competency claim.
Only 3 active trials company-wide (1 Phase 2 stem cell, 1 Phase 1 generic combo) indicates minimal clinical execution velocity for a public biotech.

Pipeline & Clinical Trials

NoaScope

Chest Pathology

N/A

Clinical Trials (1)

NCT05252130Comparison of NoaScope to the Conventional Stethoscope for Auscultation of Heart and Lung Sounds

N/A

Laguna Thrombectomy System

Pulmonary Embolism

N/A

Clinical Trials (1)

NCT06041594Treating Pulmonary Embolism With Laguna Thrombectomy System (TRUST)

N/A

Artificial Intelligence Algorithm

Respiratory

N/A

Clinical Trials (1)

NCT05268263Feasibility of AI-based Classification of Normal, Wheeze and Crackle Sounds From Stethoscope in Clinical Settings

N/A

IVL procedures

Coronary Disease

N/A

Drospirenone+ Ethinyl Estradiol Tablets-Test product

Innova Therapeutics

About Innova Therapeutics

Why Work Here

Key Products

Watch Out For

Products & Portfolio (2)

Pipeline & Clinical Trials

Open Jobs (0)

Visa Sponsorship